These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

992 related articles for article (PubMed ID: 29475723)

  • 1. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
    Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
    Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
    Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Lunning M; Vose J; Nastoupil L; Fowler N; Burger JA; Wierda WG; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Sportelli P; Miskin HP; Weiss MS; O'Brien S
    Blood; 2019 Nov; 134(21):1811-1820. PubMed ID: 31558467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
    Davids MS; O'Connor OA; Jurczak W; Samaniego F; Fenske TS; Zinzani PL; Patel MR; Ghosh N; Cheson BD; Derenzini E; Brander DM; Reeves JA; Knopińska-Posłuszny W; Allan JN; Phillips T; Caimi PF; Lech-Maranda E; Burke JM; Agajanian R; Pettengell R; Leslie LA; Cheah CY; Fonseca G; Essell J; Chavez JC; Pagel JM; Sharman JP; Hsu Y; Miskin HP; Sportelli P; Weiss MS; Flinn IW
    Blood Adv; 2021 Dec; 5(23):5332-5343. PubMed ID: 34547767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.
    Pagel JM; Soumerai JD; Reddy N; Jagadeesh D; Stathis A; Asch A; Salman H; Kenkre VP; Iasonos A; Llorin-Sangalang J; Li J; Zelenetz AD
    Lancet Oncol; 2022 Aug; 23(8):1021-1030. PubMed ID: 35835137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
    Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
    Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
    Mato AR; Ghosh N; Schuster SJ; Lamanna N; Pagel JM; Flinn IW; Barrientos JC; Rai KR; Reeves JA; Cheson BD; Barr PM; Kambhampati S; Lansigan F; Pu JJ; Skarbnik AP; Roeker L; Fonseca GA; Sitlinger A; Hamadeh IS; Dorsey C; LaRatta N; Weissbrot H; Luning Prak ET; Tsao P; Paskalis D; Sportelli P; Miskin HP; Weiss MS; Svoboda J; Brander DM
    Blood; 2021 May; 137(20):2817-2826. PubMed ID: 33259589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
    Fowler NH; Samaniego F; Jurczak W; Ghosh N; Derenzini E; Reeves JA; Knopińska-Posłuszny W; Cheah CY; Phillips T; Lech-Maranda E; Cheson BD; Caimi PF; Grosicki S; Leslie LA; Chavez JC; Fonseca G; Babu S; Hodson DJ; Shao SH; Burke JM; Sharman JP; Law JY; Pagel JM; Miskin HP; Sportelli P; O'Connor OA; Weiss MS; Zinzani PL
    J Clin Oncol; 2021 May; 39(15):1609-1618. PubMed ID: 33683917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
    Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
    Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
    Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
    Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
    Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
    Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
    Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.